Pharmaceutical company Chiesi Group has launched a corporate venture capital fund, Chiesi Ventures, targeting companies focusing on the treatment of rare diseases.
Italy-based pharmaceutical and specialist medicine company Chiesi Group has formed Chiesi Ventures, a corporate venture capital fund to target early-stage investment opportunities in companies focused on the treatment of rare diseases.
The fund, which will operate as an independent investment vehicle while maintaining a strategic connection with the Chiesi Group, has been formed in collaboration with life sciences focused venture capital firm A.M Pappas & Associates.
Chiesi Ventures will be based in the US and Italy and will focus on…
